Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 301

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 1B
Chunk 301
---
 XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document

    X

    101.SCH
     
    Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents

    X

    104
     
    Cover Page formatted as Inline XBRL and contained in Exhibit 101

    X

# Indicates management contract or compensatory plan.  

† Portions of this exhibit have been omitted for confidentiality purposes.

* These certifications are being furnished solely to accompany this annual report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 

^ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.

149

SIGNATURES 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this annual report to be signed on its behalf by the undersigned, thereunto duly authorized. 

    PHATHOM PHARMACEUTICALS, INC.

    /s/ Terrie Curran

    Terrie CurranChief Executive Officer

Date: March 6, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this annual report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

    Signature
     
    Title
     
    Date

    /s/ Terrie CurranTerrie Curran
     
    President, Chief Executive Officer andDirector (Principal Executive Officer)
     
    March 6, 2025

    /s/ Molly HendersonMolly Henderson
     
    Chief Financial and Business Officer (Principal Financial and Accounting Officer)
     
    March 6, 2025

    *Michael F. Cola
     
    Director
     
    March 6, 2025

    *Frank Karbe
     
    Director
     
    March 6, 2025

    *Heidi